Business Segments · Asset impairment
Business Segments — Asset impairment
Incyte Business Segments — Asset impairment remained flat by 0.0% to $19.07M in Q4 2025 compared to the prior quarter. Over 2 years (FY 2023 to FY 2025), Business Segments — Asset impairment shows an upward trend with a 268.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ1 2023
Last reportedQ4 2025Feb 10, 2026
Rolls up toImpairment Charges
How to read this metric
An increase suggests that previous investments in R&D or acquisitions are underperforming or have lower commercial potential than originally anticipated.
Detailed definition
This represents a non-cash charge taken when the carrying value of an asset, such as acquired intellectual property or i...
Peer comparison
Standard accounting practice for pharmaceutical companies; high frequency of impairment often indicates aggressive or unsuccessful M&A strategies.
Metric ID:
incy_segment_reportable_segment_asset_impairmentHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $5.63M | $0.00 | $76.28M |
| YoY Change | — | -100.0% | — |
Range$0.00 – $76.28M
CAGR+268.0%
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's business segments — asset impairment?
- Incyte (INCY) reported business segments — asset impairment of $19.07M in Q4 2025.
- What is the long-term trend for Incyte's business segments — asset impairment?
- Over 2 years (2023 to 2025), Incyte's business segments — asset impairment has grown at a 268.0% compound annual growth rate (CAGR), from $5.63M to $76.28M.
- What does business segments — asset impairment mean?
- A non-cash charge reflecting a reduction in the value of the company's assets.